Stock Research for BPTH


Featured Broker: Ally Invest

Get the due diligence for another stock.


BPTH Stock Chart & Research Data

The BPTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BPTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


BPTH Due diligence Resources & Stock Charts

The BPTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BPTH Detailed Price Forecast - CNN Money CNN View BPTH Detailed Summary - Google Finance
Yahoo View BPTH Detailed Summary - Yahoo! Finance Zacks View BPTH Stock Research & Analysis -

Stock Analysis

TradeIdeas View BPTH Trends & Analysis - Trade-Ideas Barrons View BPTH Major Holders - Barrons
NASDAQ View BPTH Call Transcripts - NASDAQ Seeking View BPTH Breaking News & Analysis - Seeking Alpha
Spotlight View BPTH Annual Report - OTC Report View BPTH OTC Short Report -
TradeKing View BPTH Fundamentals - TradeKing Charts View BPTH SEC Filings - Bar Chart
WSJ View Historical Prices for BPTH - The WSJ Morningstar View Performance/Total Return for BPTH - Morningstar
MarketWatch View the Analyst Estimates for BPTH - MarketWatch CNBC View the Earnings History for BPTH - CNBC
StockMarketWatch View the BPTH Earnings - StockMarketWatch MacroAxis View BPTH Buy or Sell Recommendations - MacroAxis
Bullish View the BPTH Bullish Patterns - American Bulls Short Pains View BPTH Short Pain Metrics -

Social Media Mentions

StockTwits View BPTH Stock Mentions - StockTwits PennyStocks View BPTH Stock Mentions - PennyStockTweets
Twitter View BPTH Stock Mentions - Twitter Invest Hub View BPTH Investment Forum News - Investor Hub
Yahoo View BPTH Stock Mentions - Yahoo! Message Board Seeking Alpha View BPTH Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for BPTH - Insider Cow View Insider Transactions for BPTH - Insider Cow
CNBC View BPTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BPTH - OTC Markets
Yahoo View Insider Transactions for BPTH - Yahoo! Finance NASDAQ View Institutional Holdings for BPTH - NASDAQ

Stock Charts

FinViz View BPTH Stock Insight & Charts - StockCharts View BPTH Investment Charts -
BarChart View BPTH Stock Overview & Charts - BarChart Trading View View BPTH User Generated Charts - Trading View

Latest Financial News for BPTH

Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting
Posted on Wednesday April 18, 2018

Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that data from pre-clinical studies supporting the potential of prexigebersen (BP1001, liposomal Grb2 antisense), in the treatment of solid tumors in gynecologic malignancies were presented in a poster at the annual meeting of the American Association for Cancer Research (AACR), which took place in Chicago, IL. The poster titled, “Grabbing GRB2: The use of Liposome-incorporated Grb2 antisense oligonucleotides as a novel therapy in gynecologic malignancies,” was presented by Olivia D. Lara, M.D., University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology during the Experimental and Molecular Therapeutics Poster Session.  The data summarize results from studies investigating the expression of GRB2 in a series of in vitro experiments in high-grade serous (HGSC) and uterine (UC) carcinoma models.  The study also examined the biological effects of prexigebersen in HGSC mice models (OVCAR 5), first in a dose-defining experiment then in combination with standard dose paclitaxel.

Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Posted on Monday April 09, 2018

Stock Monitor: Bio-Path Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / has just released a free research report on Aradigm Corp. (NASDAQ: ARDM ). If you ...

Bio-Path Leukemia Combo Study Shows Positive Early Data
Posted on Wednesday April 04, 2018

Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.

Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today
Posted on Tuesday April 03, 2018

The other bit of good news for BPTH stock today was financial results for its fiscal full year of 2017. During the year, the company reported a net loss of $8.1 million, or 80 cents per share. This is a wider net loss than the $6.8 million, or 73 cents per share from the year prior.

Enter a stock symbol to view the stock details.